

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 64652

Title: Epigenetic mechanisms of liver tumor resistance to immunotherapy

Reviewer's code: 04152279

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: France

Manuscript submission date: 2021-02-23

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-02-25 06:31

Reviewer performed review: 2021-03-02 14:29

Review time: 5 Days and 7 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

This article provides a comprehensive review of the mechanisms of human immunity. The article first introduces the basics of immune mechanisms, starting with the activation and decay mechanisms of T cells, further introducing the PD-1/PDL-1 axis, the CTLA4/CD80-CD86 axis, further discussing tumor-infiltrating immune cells including: immune desert, immune excluded or inflamed tumors, successes and limitations of immunotherapy for hepatocellular carcinoma (including some new therapeutic options in phase III studies including: anti-PD-1 tislelizumab and Camrelizumab), and the successes and limitations of DNA methylation and DNMT inhibitors, histone modifications and targeted drugs, respectively. The therapeutic strategies of ICIs in combination with epigenetic drugs and the efficacy of the corresponding drugs in combination with ICIs. The article is logically rigorous and sufficiently detailed. The review of the basic mechanisms of immunity is very extensive, probably because of the few studies on liver cancer itself, and the article reviews extensively the relevant literature on blood and intestinal tumors, which accordingly makes the immune resistance mechanisms causing liver cancer appear to be on the low side.